Noddi is a disruptor within automotive maintenance and enables convenient & cost efficient home-delivered car maintenance though modern UX and logistics technology. Our focus on awesome booking experiences, and logistics automation enable us to deliver car maintenance services such as wheel change and car detailing directly to your home at the same prices you have to pay in a traditional garage.

Letterlife is the first tool allowing females with ADHD to visualize the interplay of hormones, ADHD-symptoms, and everyday functioning across the menstrual cycle and the female lifespan. By tracking hormonal fluctuations, ADHD-symptoms, personal challenges, and pharmacological treatment we empower women, encourage self-efficacy and improve self-care. Today females are diagnosed 5 years later than men and untreated ADHD results a 13 year shorter life expectancy. Letterlife constitutes a data driven, gender sensitive base for shared health care decision making. The key lies in linking individualized data to health care registers, providing women with the guidance needed to navigate the complex interplay between mental and reproductive health.

What we doOur mission is to empower people to follow their dreams and pave their own path.With a long and colorful background, we have been painting big city streets pink with a Norwegian touch since 2003. However, the time has now come to move out from Grandma's house in Stryn and into the city of Oslo, and to start the writing of - a new chapter in the Moods story.

indyRIOT offers a turnkey Community and Networking Solution that provides complete functionality out of the box. It is white-labeled software as a service (SaaS) that enables our clients to fast launch their own fully branded, independent community. It doesn’t mean you can’t bootstrap off another network, but ultimately, It's your community - Own it!

Apotek 1 er Norges største apotekkjede og vi er i stadig vekst. Hos oss jobber ca. 3500 dedikerte medarbeidere, og vi er også landets største farmasøytiske arbeidsgiver. Vi har en stolt kultur med klare ambisjoner om alltid å leve opp til vårt slagord 'Vår kunnskap - din trygghet' i våre kundemøter. Kompetanse og kvalitet er kjernen for vår virksomhet, og derfor er faglig og personlig videreutvikling av våre medarbeidere helt sentralt i kjeden. I Apotek 1 er vi opptatt av å etterleve våre verdier som er: pålitelig, frisk, engasjert og nær. Vi bestreber at dette skal prege alle ansatte, alle beslutninger, alle handlinger og alle mål i selskapet. Apotek 1 Gruppen AS er eiet av den tyske Phoenix-gruppen. Servicekontor og distribusjonsenhet ligger på Lørenskog i Akershus. Vi er landets største leverandør av legemidler pakket i multidose, samt legemidler og tjenester til kommunehelsetjenesten, blant annet legemiddelgjennomganger.

Med-Storm's Skin Conductance Algesimeter (SCA) uses the principle of skin conductance to measure pain, allowing us to titrate the right amount of pain medication for each, individual patient. This award-winning technology is not affected by changes in blood circulation, heart rate, hypotensia, environmental temperatures, and hypoxia, and shows low variation between individuals at the same level of pain. The pain monitor can be used on patients as young as 23 weeks of gestational age, as well as geriatric patients. MS is currently working on a miniaturized and wireless version of the SCA.

Revolusjonen er i gang! Verden endrer seg i et forrykende tempo. Innovasjon og stadig fornyelse er viktigere enn noen gang for å beholde kundene. Moderne teknologi har raskere enn noensinne gjort at IT flytter seg nærmere forretning. Nå må beslutninger tas raskt og «fail fast» er nøkkelord. Revolusjonen har såvidt begynt og i Aboveit forstår vi effekten, virkemidlene og veien til målet.   Aboveit bygger broen mellom teknologi og forretning  - Ved å ta i bruk skyens kapabiliteter hjelper vi deg med å realisere forretningsverdi og å skape fortrinn i markedet. Vi er sikre på at morgendagens vinnere er de som får mest ut av plattformene og tjenestene i skyen. Vår tilnærming til transformasjon og digitalisering vil endre måten våre kunder tenker på sky. Vi er klare for reisen og til å løfte våre kunder til nye høyder. Velkommen til Aboveit - Vi kan hjelpe deg!

Renteradar monitors our users' mortgage rates over time and compares them to the offers available in the market. We want to make the process of monitoring and comparing mortgage rates as easy as possible by creating transparency. We automatically match our users with their cheapest lenders as well as assist in the following transition. Our system uses BankID to collect the required information which makes the experience as effortless and uncomplicated as possible.

Today, legal services are provided on the premises of the legal industry. We believe in making legal services available to everyone. We do this by automating legal processes by connecting law with design and technology. So that more people are able to be their own lawyers. We are testing our solutions in the Norwegian market at the moment, but all services are built to scale internationally. Stay tuned to receive more info when the legal products built to provide access to justice is ready to launch.

We develop business with positive impact on the environment and society – creating more with less based on game changing new technologies. Our ambition is to create synergies of resources available, from the Earth, from research and between people and networks. Therefore, we have chosen Vili Vé as our name, from the two brothers of Odin who created fjords and mountains out of the resources available from Ymir. Our focus areas are cleantech and life science, our primary market is Europe and Asia, our customers and partners are major manufacturers, distributors, B2B customers and consulting companies. Our team, communication and style reflects diversity and openness, and our teamwork is based on dedication and trust. We want our customers and partners to experience us as competent, genuine and attentive – and proactively focusing on win-win solutions.

We have developed a system for calculating and supplying Solcelle, and wind power for Scandinavia. In addition to this, we have obtained a license as a power supplier, so we can offer our customers both purchases and sales of green power. Why solar cells? Sun provides energy. As an energy source, the sun is unsurpassed. Every year, the earth receives 15,000 times more energy from the sun than the earth's population uses. Even in Norway, the sun provides 1,500 times more energy than what we use. Depending on where on the globe you are, the sun provides an amount of energy from 700 to over 2,200 kWh/m2 per year.

eCommerce, B2B, and product development towards tactical, outdoor, and lifestyle products. Office and warehouse in Oslo and eCommerce presence 3 in Norway, Sweden, and Finland. 25 employees and 100MNOK revenue in 2018. We've been growing about 50% yearly over the last three years and aim to continue growing at the same speed. The young data-driven organization with ambitions to become the biggest player within our niche. Come and join us!

Oncoinvent AS is a privately held Norwegian company established in 2010. The company is committed to developing new innovative products to provide better treatment options to cancer patients. The innovations being developed by Oncoinvent AS are a result of the extensive experience with the development of radionuclide-based cancer treatments of two of the founders, Dr. Roy H. Larsen and Professor of clinical oncology Øyvind S. Bruland. Larsen and Bruland are the inventors of the first FDA and EMA-approved alpha-emitting pharmaceutical product Xofigo® (Bayer AG), as well as of the beta-emitting radio-immunotherapeutic product candidate Betalutin® (Nordic Nanovector ASA). Oncoinvent's lead product candidate, Radspherin®, is a novel alpha-emitting radioactive microsphere designed for the treatment of metastatic cancers in body cavities. Radspherin® has been shown to cause a significant reduction in tumor cell growth. It is anticipated that the product can potentially treat several forms of metastatic cancer. The first clinical indication for Radspherin® will be the treatment of peritoneal carcinomatosis. Clinical development will be conducted in collaboration with European and American clinical research centers.

Yetz is a new distribution platform for product lines such as insurance, electricity, telecom, and finance. At launch, we will offer both insurance and power. We utilize strong incentives towards our customers and partners to share the concept, by giving them an affiliate commission. Monthly payment is based on the turnover of customers they have referred. Two fully owned sister companies Yetz Strøm og Yetz Forsikring.

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.